The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Treatment strategies for stage IV lung cancer
Paul Bunn, MD, University of Colorado Cancer Center, Aurora, CO, discusses the survival rates of patients with stage IV lung cancer, which remain suboptimal. For patients who have a high PD-L1 tumor proportion score (TPS), approximately a third of patients survive 5 years after initial diagnosis, and further statistical analysis is required to assess whether co-morbidities contribute to patient mortality after the 5 year mark. Despite the lack of available therapies for patients with late stage lung cancer, Prof. Bunn highlights treatment options for early stage lung cancer including immunotherapy and tyrosine kinase inhibitors (TKIs) for patients with driver mutations. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
Disclosures
Paul Bunn, MD is a member of the DMC committee for Merck, and BMS; has received consulting fees from AZ, Lilly, Ascentage, CStone, viecure, and Imidex; and is on the Board of Directors for Verastem.
